We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Personalis Selected for Clinical Research After Successful Evaluation of Residual Disease Assay

The Personalis logo

Want a FREE PDF version of this product news?

Complete the form below and we will email you a PDF version of "Personalis Selected for Clinical Research After Successful Evaluation of Residual Disease Assay "

Listen with
Speechify
0:00
Register for FREE to listen to this article
Thank you. Listen to this article using the player above.
Read time:
 

Personalis, Inc. (Nasdaq: PSNL) has announced it will continue its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to explore ultra-sensitive molecular residual disease (MRD) measurement, including clinically relevant and personalized variant tracking, for clinical research and drug development.

 

The two companies are collaborating to evaluate the sensitivity and specificity potential of whole-genome-informed circulating tumor DNA (ctDNA) testing, while simultaneously detecting and quantifying clinically relevant mutations in ctDNA that may be used in the future to help guide therapy when cancer is detected. One trial, called CALLA, will investigate the role of ctDNA and HPV detection in plasma in locally advanced cervical cancer.

 

"Personalis designed NeXT Personal to provide ultra-high sensitivity and specificity for MRD detection. Our whole-genome, tumor-informed approach improves ctDNA measurement even when the plasma tumor fraction is exceptionally low, which is the case in multiple cancers with low mutational burden. We are pleased that AstraZeneca is prioritizing such sensitivity, with the aim of enabling earlier and more personalized interventions for patients," said Christopher Hall, President and CEO of Personalis.

 

As part of the collaboration, Personalis’ NeXT Personal assay for liquid biopsy will aim to provide ultra-sensitive measurement of MRD, on-treatment therapy resistance tracking, and better differentiation between responders and non-responders, as well as investigate the underlying mechanisms driving cancer. 

Advertisement